{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "T",
          "alt": "R",
          "position": "240"
        },
        "variant_string_id": "PARK2 T240R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal recessive juvenile parkinsonism (AR-JP) ... is characterized by selective dopaminergic neural cell death and the absence of the Lewy body... We report here that parkin is involved in protein degradation as a ubiquitin-protein ligase...",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to impaired protein degradation due to parkin's dysfunction as a ubiquitin-protein ligase.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We report here that parkin is involved in protein degradation as a ubiquitin-protein ligase collaborating with the ubiquitin-conju- gating enzyme UbcH7, and that mutant parkins from AR-JP patients show loss of the ubiquitin-protein ligase activity.",
          "judgment": "Yes",
          "reasoning": "The assay used, measuring ubiquitin-protein ligase activity, directly assesses parkin's role in protein degradation, which is central to the defined disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Fig. 5b, Loss of in vitro ubiquitination activity in mutant IP-parkins. The ubiquitination assay was similar to that described in (a), except that various mutant Myc-tagged parkins were used.",
          "judgment": "Yes",
          "reasoning": "The paper includes experiments with wild-type parkin, serving as a normal/negative control. Figure 5 shows data for experiments done with Myc-tagged parkins, but does not state number of replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "None of the mutant IP-parkins supported this in vitro ubiquitination (Fig. 5b), emphasizing the requirement for the Ubl domain and RING-box region.",
          "judgment": "No",
          "reasoning": "The paper uses several AR-JP-associated variants, which were found by sequencing, and are assumed to be pathogenic. There is no mention of confirmed benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Not applicable. No statistical analysis of ubiquitination activity is mentioned.",
          "judgment": "No",
          "reasoning": "The paper does not include statistical analyses to estimate or calculate OddsPath for the functional data. Only visual observation of activity differences are mentioned.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper tests several variants with loss of function but does not quantify and use multiple benign or pathogenic controls.",
          "judgment": "N/A",
          "reasoning": "There is one pathogenic variant control and a wild-type control. Therefore the total number of benign/pathogenic variant controls <10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The PARK2 T240R variant shows a loss of ubiquitination activity in vitro, indicating a pathogenic effect and is consistent with the paper's aim. The functional evidence strength is PS3_supporting due to basic controls and the lack of an OddsPath calculation."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "P",
          "position": "42"
        },
        "variant_string_id": "PARK2 R42P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal recessive juvenile parkinsonism (AR-JP) ... is characterized by selective dopaminergic neural cell death and the absence of the Lewy body... We report here that parkin is involved in protein degradation as a ubiquitin-protein ligase...",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to impaired protein degradation due to parkin's dysfunction as a ubiquitin-protein ligase.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We report here that parkin is involved in protein degradation as a ubiquitin-protein ligase collaborating with the ubiquitin-conju- gating enzyme UbcH7, and that mutant parkins from AR-JP patients show loss of the ubiquitin-protein ligase activity.",
          "judgment": "Yes",
          "reasoning": "The assay used, measuring ubiquitin-protein ligase activity, directly assesses parkin's role in protein degradation, which is central to the defined disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Fig. 5b, Loss of in vitro ubiquitination activity in mutant IP-parkins. The ubiquitination assay was similar to that described in (a), except that various mutant Myc-tagged parkins were used.",
          "judgment": "Yes",
          "reasoning": "The paper includes experiments with wild-type parkin, serving as a normal/negative control. Figure 5 shows data for experiments done with Myc-tagged parkins, but does not state number of replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "None of the mutant IP-parkins supported this in vitro ubiquitination (Fig. 5b), emphasizing the requirement for the Ubl domain and RING-box region.",
          "judgment": "No",
          "reasoning": "The paper uses several AR-JP-associated variants, which were found by sequencing, and are assumed to be pathogenic. There is no mention of confirmed benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Not applicable. No statistical analysis of ubiquitination activity is mentioned.",
          "judgment": "No",
          "reasoning": "The paper does not include statistical analyses to estimate or calculate OddsPath for the functional data. Only visual observation of activity differences are mentioned.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper tests several variants with loss of function but does not quantify and use multiple benign or pathogenic controls.",
          "judgment": "N/A",
          "reasoning": "There is one pathogenic variant control and a wild-type control. Therefore the total number of benign/pathogenic variant controls <10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The PARK2 R42P variant shows a loss of ubiquitination activity in vitro, indicating a pathogenic effect and is consistent with the paper's aim. The functional evidence strength is PS3_supporting due to basic controls and the lack of an OddsPath calculation."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "Q",
          "alt": "STOP",
          "position": "311"
        },
        "variant_string_id": "PARK2 Q311STOP"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal recessive juvenile parkinsonism (AR-JP) ... is characterized by selective dopaminergic neural cell death and the absence of the Lewy body... We report here that parkin is involved in protein degradation as a ubiquitin-protein ligase...",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to impaired protein degradation due to parkin's dysfunction as a ubiquitin-protein ligase.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We report here that parkin is involved in protein degradation as a ubiquitin-protein ligase collaborating with the ubiquitin-conju- gating enzyme UbcH7, and that mutant parkins from AR-JP patients show loss of the ubiquitin-protein ligase activity.",
          "judgment": "Yes",
          "reasoning": "The assay used, measuring ubiquitin-protein ligase activity, directly assesses parkin's role in protein degradation, which is central to the defined disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Fig. 5b, Loss of in vitro ubiquitination activity in mutant IP-parkins. The ubiquitination assay was similar to that described in (a), except that various mutant Myc-tagged parkins were used.",
          "judgment": "Yes",
          "reasoning": "The paper includes experiments with wild-type parkin, serving as a normal/negative control. Figure 5 shows data for experiments done with Myc-tagged parkins, but does not state number of replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "None of the mutant IP-parkins supported this in vitro ubiquitination (Fig. 5b), emphasizing the requirement for the Ubl domain and RING-box region.",
          "judgment": "No",
          "reasoning": "The paper uses several AR-JP-associated variants, which were found by sequencing, and are assumed to be pathogenic. There is no mention of confirmed benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Not applicable. No statistical analysis of ubiquitination activity is mentioned.",
          "judgment": "No",
          "reasoning": "The paper does not include statistical analyses to estimate or calculate OddsPath for the functional data. Only visual observation of activity differences are mentioned.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper tests several variants with loss of function but does not quantify and use multiple benign or pathogenic controls.",
          "judgment": "N/A",
          "reasoning": "There is one pathogenic variant control and a wild-type control. Therefore the total number of benign/pathogenic variant controls <10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The PARK2 Q311STOP variant shows a loss of ubiquitination activity in vitro, indicating a pathogenic effect and is consistent with the paper's aim. The functional evidence strength is PS3_supporting due to basic controls and the lack of an OddsPath calculation."
    }
  ]
}
